Daily Roundup | ArriVent’s Lung Cancer Pill Hits Setback & Alector’s $100M Genentech Deal

<p>ArriVent's firmonertinib missed its Phase 3 primary progression-free-survival endpoint in lung cancer, with its next step still undecided; this delayed Tuesday edition was recorded October 6. Alector grants Genentech worldwide rights to preclinical Parkinson's program AL050 for $100 million committed upfront and up to $1.17 billion in milestones, with brain delivery untested in people. FDA seeks public input on early ibogaine trials—not an approval—and ViiV reports investigational Cabenuva (cabotegravir/rilpivirine) results in people with detectable HIV, without rates, confidence intervals or detailed safety. Forbion raises €2.3 billion in fund commitments, with first investments already made.</p><p>Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at <a href="https://thepharmacloseout.com" rel="ugc noopener noreferrer" target="_blank">thepharmacloseout.com</a>.</p>